VEGF gene delivery for treatment of ischemic cardiovascular disease

Trends Cardiovasc Med. 2002 Apr;12(3):108-14. doi: 10.1016/s1050-1738(01)00158-x.


There are increasing numbers of patients with ischemic myocardial disease not amenable to traditional methods of revascularization. These patients may benefit from new research into the use of naturally occurring angiogenic compounds, such as vascular endothelial growth factor (VEGF) for re-establishing blood flow into regions of hibernating myocardium. Animal studies and human clinical trials evaluating VEGF demonstrate increases in myocardial perfusion after treatment, with some patients reporting improvement in anginal symptoms. Further research into the ideal form of VEGF therapy (protein, plasmid, or adenoviral) and delivery method (intracoronary, intramyocardial, or epicardial) seems justified.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Endothelial Growth Factors / administration & dosage
  • Endothelial Growth Factors / genetics
  • Endothelial Growth Factors / therapeutic use*
  • Gene Transfer Techniques
  • Genetic Therapy
  • Humans
  • Lymphokines / administration & dosage
  • Lymphokines / genetics
  • Lymphokines / therapeutic use*
  • Myocardial Ischemia / therapy*
  • Neovascularization, Physiologic / drug effects
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors


  • Endothelial Growth Factors
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors